An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Cho, Hyun Il ^a   Jung, Soo Hyun ^a   Sohn, Hyun Jung ^a   Celis, Esteban ^b   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

cancer vaccine; dendritic cells; heterologous prime boost vaccination; multivalent CD8+ T cells; peptide based vaccine; tumor immunity

Indexed keywords

CANCER VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; GAMMA INTERFERON; PEPTIDE VACCINE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ERADICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN;

EID: 84941774508     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1043504     Document Type: Article

References (41)

1. M.Dougan, G.Dranoff. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83-117; PMID:19007331; http://dx.doi.org/10.1146/annurev.immunol.021908.132544
2. + T cells. Cancer Res 2003; 63:4095-100; PMID:12874012
3. C.J.Melief, W.M.Kast. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Semin Cancer Biol 1991; 2:347-54; PMID:1773050
4. M.Holzel, A.Bovier, T.Tuting. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013; 13:365-76; PMID:23535846; http://dx.doi.org/10.1038/nrc3498
5. R.M.Steinman, M.Witmer-Pack, K.Inaba. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329:1-9; PMID:8379358; http://dx.doi.org/10.1007/978-1-4615-2930-9_1
6. A.Vasaturo, S.Di Blasio, D.G.Peeters, C.C.de Koning, J.M.de Vries, C.G.Figdor, S.V.Hato. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol 2013; 4:417; PMID:24348481; http://dx.doi.org/10.3389/fimmu.2013.00417
7. F.Benencia, L.Sprague, J.McGinty, M.Pate, M.Muccioli. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012; 2012:425476; PMID:22505809; http://dx.doi.org/10.1155/2012/425476
8. H.I.Cho, E.Celis. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 2009; 69:9012-9; PMID:19903852; http://dx.doi.org/10.1158/0008-5472.CAN-09-2019
9. D.Assudani, H.I.Cho, N.DeVito, N.Bradley, E.Celis. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 2008; 68:9892-9; PMID:19047170; http://dx.doi.org/10.1158/0008-5472.CAN-08-3134
10. H.I.Cho, E.Reyes-Vargas, J.C.Delgado, E.Celis. A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res 2012; 72:1986-95; PMID:22367213; http://dx.doi.org/10.1158/0008-5472.CAN-11-3246
11. H.I.Cho, K.Barrios, Y.R.Lee, A.K.Linowski, E.Celis. BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol Immunother 2013; 62:787-99; PMID:23266830; http://dx.doi.org/10.1007/s00262-012-1382-6
12. J.A.Guevara-Patino, M.E.Engelhorn, M.J.Turk, C.Liu, F.Duan, G.Rizzuto, A.D.Cohen, T.Merghoub, J.D.Wolchok, A.N.Houghton. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006; 116:1382-90; PMID:16614758; http://dx.doi.org/10.1172/JCI25591
13. J.S.Gold, C.R.Ferrone, J.A.Guevara-Patino, W.G.Hawkins, R.Dyall, M.E.Engelhorn, J.D.Wolchok, J.J.Lewis, A.N.Houghton. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170:5188-94; PMID:12734366; http://dx.doi.org/10.4049/jimmunol.170.10.5188
14. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005; 11:748-56; PMID:15951824; http://dx.doi.org/10.1038/nm1257
15. + T cell contraction is controlled by early inflammation. Nat Immunol 2004; 5:809-17; PMID:15247915; http://dx.doi.org/10.1038/ni1098
16. E.L.Pearce, H.Shen. Generation of CD8 T cell memory is regulated by IL-12. J Immunol 2007; 179:2074-81; PMID:17675465; http://dx.doi.org/10.4049/jimmunol.179.4.2074
17. + T cell generation after acute infection. J Immunol 2007; 179:53-63; PMID:17579021; http://dx.doi.org/10.4049/jimmunol.179.1.53
18. W.J.Lesterhuis, I.J.de Vries, G.Schreibelt, A.J.Lambeck, E.H.Aarntzen, J.F.Jacobs, N.M.Scharenborg, M.W.van de Rakt, A.J.de Boer, S.Croockewit et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432.CCR-11-1261
19. L.H.Butterfield. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2013; 4:454; PMID:24379816; http://dx.doi.org/10.3389/fimmu.2013.00454
20. D.W.Mullins, S.L.Sheasley, R.M.Ream, T.N.Bullock, Y.X.Fu, V.H.Engelhard. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003; 198:1023-34; PMID:14530375; http://dx.doi.org/10.1084/jem.20021348
21. I.A.Ramshaw, A.J.Ramsay. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000; 21:163-5; PMID:10740236; http://dx.doi.org/10.1016/S0167-5699(00)01612-1
22. T.Lin, S.Liang, F.Meng, Q.Han, C.Guo, L.Sun, Y.Chen, Z.Liu, Z.Yu, H.Xie et al. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer. Clin Exp Immunol 2006; 144:319-25; PMID:16634806; http://dx.doi.org/10.1111/j.1365-2249.2006.03065.x
23. L.Garcia-Hernandez Mde, A.Gray, B.Hubby, W.M.Kast. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007; 67:1344-51; PMID:17283172; http://dx.doi.org/10.1158/0008-5472.CAN-06-2996
24. D.L.Woodland. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004; 25:98-104; PMID:15102369; http://dx.doi.org/10.1016/j.it.2003.11.009
25. M.J.Estcourt, A.J.Ramsay, A.Brooks, S.A.Thomson, C.J.Medveckzy, I.A.Ramshaw. Prime-boost immunization generates a high frequency, high-avidity CD8(+) cytotoxic T lymphocyte population. Int Immunol 2002; 14:31-7; PMID:11751749; http://dx.doi.org/10.1093/intimm/14.1.31
26. H.McShane. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 2002; 4:23-7; PMID:11883691
27. S.R.Bennett, F.R.Carbone, F.Karamalis, R.A.Flavell, J.F.Miller, W.R.Heath. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80; PMID:9624004; http://dx.doi.org/10.1038/30996
28. R.R.French, V.Y.Taraban, G.R.Crowther, T.F.Rowley, J.C.Gray, P.W.Johnson, A.L.Tutt, A.Al-Shamkhani, M.J.Glennie. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007; 109:4810-5; PMID:17311995; http://dx.doi.org/10.1182/blood-2006-11-057216
29. + T cell help. J Immunol 2007; 178:2844-52; PMID:17312128; http://dx.doi.org/10.4049/jimmunol.178.5.2844
30. + T-cell expansion upon vaccinia virus challenge relies on CD40 signaling. Eur J Immunol 2014; 44:115-26; PMID:24108445; http://dx.doi.org/10.1002/eji.201343805
31. + T-cell responses in tumor-bearing hosts. Cancer Res 2005; 65:6984-9; PMID:16061684; http://dx.doi.org/10.1158/0008-5472.CAN-04-3344
32. W.Jing, J.A.Gershan, B.D.Johnson. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 2009; 113:4449-57; PMID:19182203; http://dx.doi.org/10.1182/blood-2008-11-190827
33. X.Li, E.Kostareli, J.Suffner, N.Garbi, G.J.Hammerling. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. Eur J Immunol 2010; 40:3325-35; PMID:21072887; http://dx.doi.org/10.1002/eji.201041093
34. K.Klages, C.T.Mayer, K.Lahl, C.Loddenkemper, M.W.Teng, S.F.Ngiow, M.J.Smyth, A.Hamann, J.Huehn, T.Sparwasser. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70:7788-99; PMID:20924102; http://dx.doi.org/10.1158/0008-5472.CAN-10-1736
35. N.Matsushita, S.A.Pilon-Thomas, L.M.Martin, A.I.Riker. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333:167-79; PMID:18295790; http://dx.doi.org/10.1016/j.jim.2008.01.012
36. O.Boyman, M.Kovar, M.P.Rubinstein, C.D.Surh, J.Sprent. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-7; PMID:16484453; http://dx.doi.org/10.1126/science.1122927
37. O.Boyman, J.Sprent. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12:180-90; PMID:22343569; http://dx.doi.org/10.1038/nri3156′
38. S.J.Ha, S.N.Mueller, E.J.Wherry, D.L.Barber, R.D.Aubert, A.H.Sharpe, G.J.Freeman, R.Ahmed. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008; 205:543-55; PMID:18332181; http://dx.doi.org/10.1084/jem.20071949
39. S.L.Topalian, C.G.Drake, D.M.Pardoll. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24:207-12; PMID:22236695; http://dx.doi.org/10.1016/j.coi.2011.12.009
40. S.Spranger, R.M.Spaapen, Y.Zha, J.Williams, Y.Meng, T.T.Ha, T.F.Gajewski. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
41. J.Landsberg, J.Kohlmeyer, M.Renn, T.Bald, M.Rogava, M.Cron, M.Fatho, V.Lennerz, T.Wölfel, M.Hölzel et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012; 490:412-6; PMID:23051752; http://dx.doi.org/10.1038/nature11538